EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Paediatric and Adult Solid Tumours Exhibiting NTRK Gene Fusions in Australia, 2020–2044: A Population‐Based Statistical Modelling Study

Qingwei Luo, Yoon-Jung Kang, Jeff Cuff, John Zalcberg, Karen Canfell, Julia Steinberg

Cancer Medicine · 2026-05 · 15 (5)

DOI: 10.1002/cam4.71805 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 20.05.2026. Verfasst von Qingwei Luo und 5 weiteren Autor:innen. Beteiligte Einrichtung: The Daffodil Centre, The University of Sydney, and Cancer Council NSW, Sydney, New South Wales, Australia. Hauptthemen laut MEDLINE: Neoplasms, Oncogene Proteins, Fusion, Gene Fusion, Receptor, trkA. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Cancer Institute NSW Career Development Fellowship, Australian Government, The National Health and Medical Research Council of Australia.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

TRK inhibitors targeting NTRK fusion‐positive cancers have the potential to improve patient outcomes, but also have high costs. We report the first long‐term projections of cancer prevalence associated with NTRK gene fusions in Australia, to 2044.

Methods

We analysed national Australian Institute of Health and Welfare incidence (1982–2019) and survival (1991–2019), NSW Enduring Cancer Data Linkage incidence (1982–2019) and survival data (1982–2019). We projected 1‐year to 5‐year cancer prevalence using validated statistical methods, for all stages combined, advanced disease at diagnosis (here, distant metastasis/lymph node involvement), and advanced disease after progression post‐diagnosis. We estimated prevalence for all paediatric cancers combined (age < 18 years at diagnosis), all adult solid cancers combined, 18 cancer types/groups, and 5 cancer sub‐types relevant to current Australian government subsidies of TRK inhibitors.

Results

For all solid cancers combined, we project increasing prevalence of individuals who were diagnosed with tumours exhibiting NTRK gene fusions, primarily due to population growth and ageing. For example, for 2‐year prevalence (aligning with 2.5 years average treatment assumed in previous economic assessments for a TRK inhibitor subsidy), the projected increases from 2019 to 2044 are: all stages combined, paediatric cancers 80 to 106 (+ 32.5%), adult cancers 645 to 970 (+ 50.4%); advanced disease at diagnosis, paediatric cancers 19 to 23 (+ 21.1%), adult cancers 185 to 261 (+ 41.1%); advanced disease after progression post‐diagnosis, paediatric cancers 22 to 30 (+ 36.4%), adult cancers 110 to 180 (+ 63.6%).

Conclusion

The results from this study can support healthcare planning and budget forecasts, including for different potential government treatment subsidy scenarios.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsOncogene Proteins, FusionGene FusionReceptor, trkAHumansAdultChildAustraliaFemaleAdolescentMalePrevalenceChild, PreschoolModels, StatisticalYoung AdultMiddle AgedInfantAged

Stichwörter der Autor:innen

NTRK gene fusionsTRK fusion cancerTRK inhibitorcancer prevalencepan‐tumour biomarkerstatistical projections

Substanzen

Oncogene Proteins, FusionReceptor, trkA

Autor:innen und Institutionen

  • The Daffodil Centre, The University of Sydney, and Cancer Council NSW, Sydney, New South Wales, Australia.
  • Cancer Elimination Collaboration, School of Public Health, The University of Sydney, Sydney, New South Wales, Australia.
  • Research Advocate, the Daffodil Centre, Sydney, New South Wales, Australia.
  • Faculty of Science Biotech and Biomolecular Science, University of New South Wales, Sydney, New South Wales, Australia.
  • Department of Medical Oncology, Alfred Health and School of Public Health and Preventive Medicine, Faculty of Medicine, Monash University, Melbourne, Victoria, Australia.

Förderung

  • Cancer Institute NSW Career Development Fellowship
  • Australian Government
  • The National Health and Medical Research Council of Australia

Zitieren

APA

Luo, Q., Kang, Y. J., Cuff, J., Zalcberg, J., Canfell, K., & Steinberg, J. (2026). Paediatric and Adult Solid Tumours Exhibiting NTRK Gene Fusions in Australia, 2020–2044: A Population‐Based Statistical Modelling Study. Cancer Medicine, 15(5). https://doi.org/10.1002/cam4.71805

Vancouver

Luo Q, Kang YJ, Cuff J, Zalcberg J, Canfell K, Steinberg J. Paediatric and Adult Solid Tumours Exhibiting NTRK Gene Fusions in Australia, 2020–2044: A Population‐Based Statistical Modelling Study. Cancer Medicine. 2026;15(5). doi:10.1002/cam4.71805

BibTeX
@article{Luo2026,
  author = {Luo, Qingwei and Kang, Yoon-Jung and Cuff, Jeff and Zalcberg, John and Canfell, Karen and Steinberg, Julia},
  title = {Paediatric and Adult Solid Tumours Exhibiting NTRK Gene Fusions in Australia, 2020–2044: A Population‐Based Statistical Modelling Study},
  journal = {Cancer Medicine},
  year = {2026},
  volume = {15},
  number = {5},
  doi = {10.1002/cam4.71805}
}
Kostenlos starten →